Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Figure 3 Meta-regression showing the time dependent increase in explant.
A: Q = 9.35; P = 0.002 and reoperation panel; B: Q = 20.3; P < 0.001 rates after sacral neurostimulation initiation.
- Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
- URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294